4.88

4.27% +0.20

Vanda Pharmaceuticals Inc (VNDA)

Overview News Price History Option Chain Financials Discussions Forecast

Vanda Pharmaceuticals Inc stock is currently priced at $4.88, with a 24-hour trading volume of 654.11K. It has seen a +4.27% increased in the last 24 hours and a -3.37% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.73 pivot point. If it approaches the $4.90 resistance level, significant changes may occur.

Previous Close:

$4.68

Open:

$4.71

24h Volume:

654.11K

Market Cap:

$284.01M

Revenue:

$192.64M

Net Income/Loss:

$2.51M

P/E Ratio:

18.07

EPS:

0.27

Net Cash Flow:

$12.42M

1W Performance:

+5.63%

1M Performance:

-3.37%

6M Performance:

+7.96%

1Y Performance:

-23.63%

1D Range:

$4.7001

$4.91

52W Range:

$3.295

$7.00

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name

Vanda Pharmaceuticals Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

202-734-3400

Address

2200 Pennsylvania Avenue NW, Suite 300E, Washington

Employee

273

Twitter

Next Earnings Date

2024-05-17

Latest SEC Filings

VNDA's Discussions on Twitter

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-22	Downgrade	Jefferies	Buy → Hold
May-12-21	Initiated	BofA Securities	Buy
Jan-14-21	Downgrade	Citigroup	Buy → Neutral
Oct-29-20	Upgrade	Citigroup	Neutral → Buy
Jun-09-20	Downgrade	Citigroup	Buy → Neutral
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy
Nov-07-19	Downgrade	Citigroup	Buy → Neutral
Aug-01-19	Upgrade	Citigroup	Neutral → Buy
Jul-25-19	Downgrade	Stifel	Buy → Hold
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Sep-14-17	Reiterated	Piper Jaffray	Overweight
Jun-27-17	Resumed	Piper Jaffray	Overweight
May-26-17	Initiated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Oppenheimer	Outperform
Nov-09-16	Initiated	Aegis Capital	Buy
Oct-06-16	Resumed	Jefferies	Buy

View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know

Zacks Investment Research

Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views

Benzinga

Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data

Vanda Pharmaceuticals Inc (VNDA) Revenue 2024

VNDA reported a revenue (TTM) of $192.64 million for the quarter ending December 31, 2023, a -24.27% decline year-over-year.

Vanda Pharmaceuticals Inc (VNDA) Net Income 2024

VNDA net income (TTM) was $2.51 million for the quarter ending December 31, 2023, a -60.02% decrease year-over-year.

Vanda Pharmaceuticals Inc (VNDA) Cash Flow 2024

VNDA recorded a free cash flow (TTM) of $12.42 million for the quarter ending December 31, 2023, a -60.33% decrease year-over-year.

Vanda Pharmaceuticals Inc (VNDA) Earnings per Share 2024

VNDA earnings per share (TTM) was $0.0524 for the quarter ending December 31, 2023, a -56.33% decline year-over-year.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.